Powering Precision Oncology
CGP powered by TruSight™ Oncology 500 ctDNA v2 and TruSight™ Oncology 500 High-Throughput
TSO 500 for Pharma Partners
Pan‑tumor CGP solutions across tissue and liquid biopsy, providing enhanced coverage and sensitivity
TSO 500 HT and TSO 500 ctDNA v2
Unlock the complexities of every tumor
TSO 500 HT and TSO 500 ctDNA v2 provide enhanced coverage, sensitivity, and speed, supporting biopharma partners in confident, data-driven decision making. From biomarker discovery and target validation to resistance detection, clinical trial enrollment, longitudinal monitoring, and patient stratification – TSO 500 delivers the molecular clarity needed to advance precision oncology.
Our clinically and analytically validated CGP tests – spanning both tissue and liquid biopsy – work seamlessly to uncover comprehensive molecular insights across pan-solid tumor indications.
TSO 500 HT
Maximize insights. Minimize tissue. One comprehensive panel
TSO 500 HT streamlines solid tumor profiling by combining DNA and RNA sequencing into a single, comprehensive assay. This approach enables biomarker identification, target validation, and patient stratification, helping to accelerate precision oncology development.
- 517 cancer-relevant genes
- DNA: SNVs, InDels and CNVs – 517 genes
- RNA: Fusions & splice variants – 55 genes
- IO gene signatures - MSI and TMB
- High performance DNA + RNA sequencing for optimized fusion detection
| Variant Class | Analytical Sensitivity | Specificity | Accuracy |
|---|---|---|---|
| SNVs | 95.2% | >99.9% | 99.9% |
| InDels | 92.4% | >99.9% | 99.9% |
| CNVs | 100% | 99.6% | 99.7% |
| Fusions | 94.4% | 99.9% | 99.7% |
| LOD | 5% VAF for small variants CNV reporting cutoff is 2.2X fold-change |
Discover how our CGP solutions can support you—get in touch.
TSO 500 ctDNA v2
Simple blood sample. Deep insights. One comprehensive panel
A comprehensive, noninvasive liquid biopsy (ctDNA) lab developed test for solid tumors - enabling biomarker discovery, clinical trial enrollment, and longitudinal monitoring - empowering data-driven decisions even when tumor tissue is limited or unavailable.
- 514 cancer-relevant genes
- SNVs and InDels – 514 genes
- CNVs – 58 genes
- Fusions – 23 genes
- IO gene signatures (MSI-H status; bTMB score)
- High performance ctDNA assay
| Variant Class | Analytical Sensitivity | Specificity | Accuracy | LOD* |
|---|---|---|---|---|
| SNVs/InDels | 92.01% | 99.80% | 99.65% | 0.23% |
| CNVs | 95% | 99.86% | 99.82% | 1.20 fold |
| Fusions | 100% | 100% | 100% | 0.5% |
*LOD90 at 30ng input
Expertise You Can Trust. Resources You Can Act On.
Explore our webinars, white papers, and other valuable resources